The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
Abstract The biology of breast cancer response to neoadjuvant therapy is underrepresented in the literature and provides a window-of-opportunity to explore the genomic and microenvironment modulation of tumours exposed to therapy. Here, we characterised the mutational, gene expression, pathway enric...
Guardado en:
Autores principales: | Leticia De Mattos-Arruda, Javier Cortes, Juan Blanco-Heredia, Daniel G. Tiezzi, Guillermo Villacampa, Samuel Gonçalves-Ribeiro, Laia Paré, Carla Anjos Souza, Vanesa Ortega, Stephen-John Sammut, Pol Cusco, Roberta Fasani, Suet-Feung Chin, Jose Perez-Garcia, Rodrigo Dienstmann, Paolo Nuciforo, Patricia Villagrasa, Isabel T. Rubio, Aleix Prat, Carlos Caldas |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/206a008b2ff14604b0c18a4e4d55bbec |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
por: G. Griguolo, et al.
Publicado: (2021) -
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Gaia Griguolo, et al.
Publicado: (2021) -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Fara Brasó-Maristany, et al.
Publicado: (2020) -
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Tomás Pascual, et al.
Publicado: (2021) -
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Francesco Schettini, et al.
Publicado: (2021)